Renal Cancer - Results from #2060

Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma. May 19, 2021

Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study. May 19, 2021

Response to systemic therapy in fumarate hydratase-deficient renal cell carcinoma. May 18, 2021

Functional inhibition of cancer stemness-related protein DPP4 rescues tyrosine kinase inhibitor resistance in renal cell carcinoma. May 18, 2021

TSC loss is a clonal event in eosinophilic solid and cystic renal cell carcinoma: a multiregional tumor sampling study. May 17, 2021

Noninvasive evaluation of tumor immune microenvironment in patients with clear cell renal cell carcinoma using metabolic parameter from preoperative 2-[18F]FDG PET/CT. May 14, 2021

Identification of an apoptosis-related prognostic gene signature and molecular subtypes of clear cell renal cell carcinoma (ccRCC). May 14, 2021

Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. May 13, 2021

Prognostic Factors in De Novo Metastatic Renal Cell Carcinoma: A Report From the Latin American Renal Cancer Group. May 13, 2021

The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma. May 12, 2021

Adverse events of systemic immune-based combination therapies in the first-line treatment of patients with metastatic renal cell carcinoma: systematic review and network meta-analysis. May 12, 2021

Soluble BTN2A1 Is a Potential Prognosis Biomarker in Pre-Treated Advanced Renal Cell Carcinoma. May 11, 2021

Non-invasive urine markers for the differentiation between RCCs and oncocytoma. May 11, 2021

Association between cytoreductive nephrectomy and survival among patients with metastatic renal cell carcinoma receiving modern therapies: a systematic review and meta-analysis examining effect modification according to systemic therapy approach. May 10, 2021

Comparable survival outcome between acquired cystic disease associated renal cell carcinoma and clear cell carcinoma in patients with end-stage renal disease: a multi-institutional central pathology study. May 10, 2021

Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell Carcinoma. May 7, 2021

Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers. May 7, 2021

Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. May 6, 2021

MK-6482 as a potential treatment for von Hippel-Lindau disease-associated clear cell renal cell carcinoma. May 6, 2021

DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers. May 5, 2021

Page 104 of 457